Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial - Deodhar, A; Van den Bosch, F; Poddubnyy, D (Lancet, 2022)